This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Prince, M. E.P. Articles by Ailles, L. E. Search for Related Content PubMed PubMed Citation Articles by Prince, M. E.P. Articles by Ailles, L. E. Social Bookmarking                            What's this?

Cancer Stem Cells in Head and Neck Squamous Cell Cancer

Mark E.P. Prince, Laurie E. Ailles

From the Institute for Stem Cell Biology, Stanford University, Stanford; Regenerat, Palo Alto, CA; and the Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI

Corresponding author: Mark E.P. Prince, MD, University of Michigan, Otolaryngology-HNS, 1904 Taubman Center, 1500 East Medical Center Dr, Ann Arbor, MI 48109; e-mail: mepp{at}umich.edu

Appropriate treatment of head and neck squamous cell cancer (HNSCC) remains one of the most difficult challenges in head and neck oncology. Overall survival of patients with HNSCC remains at approximately 50% at 5 years. Surgical therapy can be mutilating and often has significant effects on swallowing, speech, and physical appearance. The addition of chemotherapy to radiation treatment has shown efficacy in organ preservation in some sites in the head and neck, but has resulted in limited improvement in survival rates. HNSCC resistance to chemotherapy has limited the usefulness of chemotherapy in the treatment of this disease. We have recently demonstrated that human head and neck squamous cell cancers contain a tumorigenic, so-called cancer stem cell, subpopulation of cells that can self-renew and produce differentiated cells that form the bulk of the tumor. These tumorigenic HNSCC cells have a distinct phenotype and can be identified by a surface marker. Current treatment for HNSCC regimens may selectively kill the differentiated cancer cells, producing tumor regression while sparing the cancer stem cells, leading to tumor regrowth and relapse. It is important for us to understand why HNSCC does not respond to chemotherapy and to identify new targeted treatments that can overcome resistance and improve patient outcomes. Further study of HNSCC stem cells will increase our knowledge of this devastating disease and allow us to develop novel treatments.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?